Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.

Tenofovir better than entecavir in acute-on-chronic liver failure due to CHB reactivation

15 Mar 2019

A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).

Moreover, white blood cell count and hepatitis B virus (HBV)-DNA reduction at 2 weeks independently predict mortality at 3 months.

At 2 weeks, patients in the TDF vs ETV group had significantly higher HBV-DNA reduction (p=0.003), lower HBV-DNA level (p=0.001), higher rate of HBV-DNA undetectability (p=0.007), lower Child-Turcotte-Pugh (CTP; p=0.003) and model for end-stage liver disease scores (p=0.002).

At 3 months, all survivors had undetectable HBV-DNA, while CTP (p=0.970) and model for end-stage liver disease scores (p=0.192) were comparable between the two groups but markedly lower compared with baseline values (p<0.01). In addition, cumulative survival rate was significantly higher in the TDF vs ETV group (p=0.025).

White blood cell count (hazard ratio [HR], 2.726; 95 percent CI, 2.691–7.897; p=0.000) and HBV-DNA reduction (HR, 0.266; 0.033–0.629; p=0.013) at 2 weeks independently predicted mortality. The two study drugs were well tolerated.

In this study, a total of 67 consecutive patients with HBV-ACLF were assigned to groups receiving daily TDF (300 mg/d; n=32) or daily ETV (0.5 mg/d; n=35). Researchers prospectively followed these patients. Overall survival at 3 months was the primary endpoint.

“ACLF can be triggered by reactivation of CHB. TDF and ETV are now the most potent antiviral agents for CHB,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.